Poor Prognostic Factors in Sickle Cell Disease Patients Infected with Covid-19 – Review of Literatures
American Journal of Laboratory Medicine
Volume 5, Issue 4, July 2020, Pages: 125-130
Received: Jul. 9, 2020;
Accepted: Jul. 30, 2020;
Published: Aug. 17, 2020
Views 303 Downloads 100
Odebiyi Hassan Abiola, Department of Haematology, Federal Medical Center, Birnin Kudu, Nigeria
Dachi Rufai Abdul, Department of Haematology and Blood Transfusion, Abubakar Tafawa Balewa University Teaching Hospital, Bauchi, Nigeria
Pindiga Kasim Muhammad, Department of Haematology and Blood Transfusion, Federal Teaching Hospital Gombe, Gombe, Nigeria
Sickle cell disease (SCD) is the co-inheritance of HbS with other abnormal haemoglobin. COVID-19 is a severe acute respiratory distress syndrome caused by coronavirus 2 infections. The immunosuppression and chronic inflammatory states in patients with SCD predispose them to severe form of COVID-19. The few case studies on sickle cell disease patients infected with COVID-19 mostly discuss the pattern of clinical presentations and laboratory changes in patients with SCD infected with COVID-19. This review of literature assesses the prognostic indicators in sickle cell disease patients infected with COVID 19 in three major case series. Some presenting symptoms and signs, presence of comorbidities and certain laboratory parameters were compared with poor outcome of patients. Poor clinical outcomes of patients in this review included: 1. Duration of admission of ≥10 days, 2. A week or more of intensive care unit admission, 3. Death of patient despite intervention while on admission, and 4. Deterioration in the presenting comorbid clinical condition. The presenting symptoms and signs, presence of comorbidities and certain laboratory parameters associated with these poor clinical outcomes were considered as poor prognostic factors. The presence of comorbidities, markedly elevated pro-inflammatory markers such as leukocytosis, IL-6, C-reactive proteins, marked elevated D-Dimer and high serum creatinine are poor prognostic factors in sickle cell disease patients with COVID-19 infection.
Odebiyi Hassan Abiola,
Dachi Rufai Abdul,
Pindiga Kasim Muhammad,
Poor Prognostic Factors in Sickle Cell Disease Patients Infected with Covid-19 – Review of Literatures, American Journal of Laboratory Medicine.
Vol. 5, No. 4,
2020, pp. 125-130.
Adekile A. What’s new in the pathophysiology of sickle cell disease? Med Princ Pr. 2013; 22 (4): 311–2.
Taiwo IA, Oloyede OA, Dosumu AO. Frequency of sickle cell genotype among the Yorubas in Lagos: Implications for the level of awareness and genetic counseling for sickle cell disease in Nigeria. J Community Genet. 2011; 2 (1): 13–8.
Carcao M, Dawn C, Uptom A, Jeremy F, Nadya C. Acute Painful episodes vaso-occlusive Crisis: Guidelines for management in Children with Sickle cell disease. Clin Pract Guidel. 2016; 5: 1–9.
Ilesanmi OO. Pathological basis of symptoms and crises in sickle cell disorder: implications for counseling and psychotherapy. Hematol Rep [Internet]. 2010/04/13. 2010 Jan 26; 2 (1): e2–e2. Available from: https://pubmed.ncbi.nlm.nih.gov/22184515
Ojo OT, Shokunbi WA. CD4+ T Lymphocytes count in sickle cell anaemia patients attending a tertiary hospital. Niger Med J [Internet]. 2014 May; 55 (3): 242–5. Available from: https://pubmed.ncbi.nlm.nih.gov/25013257
Conran N, Belcher JD. Inflammation in sickle cell disease. Clin Hemorheol Microcirc. 2018; 68 (2–3): 263–99.
Queiroz RF, Lima ES. Oxidative stress in sickle cell disease. Rev Bras Hematol Hemoter [Internet]. 2013; 35 (1): 16–7. Available from: https://pubmed.ncbi.nlm.nih.gov/23580878
Garcia NP, Júnior ALS, Soares GAS, Costa TCC, Dos Santos APC, Costa AG, et al. Sickle cell anemia patients display an intricate cellular and serum biomarker network highlighted by TCD4+CD69+ lymphocytes, IL-17/mIP-1 β, IL-12/vegf, and IL-10/IP-10 axis. J Immunol Res. 2020.
Chiappetta S, Sharma AM, Bottino V, Stier C. COVID-19 and the role of chronic inflammation in patients with obesity. Int J Obes [Internet]. 2020; 20–2. Available from: http://dx.doi.org/10.1038/s41366-020-0597-4
Zhang C, Wu Z, Li JW, Zhao H, Wang GQ. Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. Int J Antimicrob Agents. 2020; 55 (5).
Sundd P, Gladwin MT, Novelli EM. Pathophysiology of Sickle Cell Disease. Annu Rev Pathol [Internet]. 2018/10/17. 2019 Jan 24; 14: 263–92. Available from: https://pubmed.ncbi.nlm.nih.gov/30332562
Booth C, Inusa B, Obaro SK. Infection in sickle cell disease: A review. Int J Infect Dis. 2010; 14 (1): 2–12.
Topcuoglu N. Public Health Emergency of International Concern: Coronavirus Disease 2019 (COVID-19). Open Dent J. 2020; 14 (1): 71–2.
Cucinotta D, Vanelli M. WHO Declares COVID-19 a Pandemic. Acta Biomed. 2020 Mar; 91 (1): 157–60.
Tedros A. Coronavirus pandemic: Tracking the global outbreak. BBC News [Internet] [Internet]. Available from: https://www.bbc.com/news/world-51839944
Bang LS, Black RD, Hall SA, Roberts WC. Dyspnea with hemoglobin SC disease. Proc (Bayl Univ Med Cent) [Internet]. 2002; 15 (1): 86–90. Available from: http://europepmc.org/abstract/MED/16333412
Pain T, Exchange P, Anemia C, Hypertension P. Sickle Cell Disease Pulmonary Manifestations of Hemato- logic and Oncologic Diseases Haematological Diseases in the Tropics. 2014.
McCloskey KA, Meenan J, Hall R, Tsitsikas DA. COVID-19 Infection and Sickle Cell Disease: A UK Centre Experience. Br J Haematol. 2020; 1–2.
Hussain FA, Njoku FU, Saraf SL, Molokie RE, Gordeuk VR, Han J. COVID-19 infection in patients with sickle cell disease. Br J Haematol. 2020; 189 (5): 851–2.
Heilbronner C, Berteloot L, Tremolieres P, Dupic L, de Saint Blanquat L, Lesage F, et al. Patients with sickle cell disease and suspected COVID-19 in a paediatric intensive care unit. Br J Haematol. 2020; 190 (1): e21–4.
De Luna G, Habibi A, Deux JF, Colard M, d’Alexandry d’Orengiani ALPH, Schlemmer F, et al. Rapid and Severe Covid-19 Pneumonia with Severe Acute Chest Syndrome in a Sickle Cell Patient Successfully Treated with Tocilizumab. Am J Hematol. 2020; (April): 8–10..
Yeruva SLH, Paul Y, Oneal P, Nouraie M. Renal Failure in Sickle Cell Disease: Prevalence, Predictors of Disease, Mortality and Effect on Length of Hospital Stay. Hemoglobin. 2016; 40 (5): 295–9.
Panepinto JA, Pajewski NM, Foerster LM, Sabnis S, Hoffmann RG. Impact of family income and sickle cell disease on the health-related quality of life of children. Qual Life Res. 2009; 18 (1): 5.
Amr MA-M, Amin TT, Al-Omair OA. Health related quality of life among adolescents with sickle cell disease in Saudi Arabia. Pan Afr Med J. 2011; 8 (1).
Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM, et al. Comorbidity and its impact on 1,590 patients with Covid-19 in China: A nationwide analysis. Eur Respir J. 2020; 55 (5).
Guan WJ, Liang WH, He JX, Zhong NS. Cardiovascular comorbidity and its impact on patients with COVID-19. Eur Respir J. 2020; 55 (6).
Oyelade T, Alqahtani J, Canciani G. Prognosis of COVID-19 in Patients with Liver and Kidney Diseases: An Early Systematic Review and Meta-Analysis. Trop Med Infect Dis. 2020; 5 (2).
Uribarri A, Núñez IJ, Alvaro G, Victor A, Muñoz MB, Feltes G. Impact of renal function on admission in COVID - 19 patients : an analysis of the international HOPE COVID - 19 (Health Outcome Predictive Evaluation for COVID 19) Registry. J Nephrol [Internet]. 2020; 19. Available from: https://doi.org/10.1007/s40620-020-00790-5
Taylor S, Shacks S, Mitchell R, Banks A. Serum interleukin-6 levels in the steady state of sickle cell disease. J Interf Cytokine Res. 1995; 15 (12): 1061–4.
Mehta P, McAuley D, Brown M el at. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet L Engl. 2020; 10229 (395): 1033–4.
Kewan T, Covut F, Al MJ, Jaghbeer À, Rose L, Gopalakrishna K V, et al. Tocilizumab for treatment of patients with severe COVID À 19 : A retrospective cohort study. EClinicalMedicine [Internet]. 2020; 000: 100418. Available from: https://doi.org/10.1016/j.eclinm.2020.100418
Zhang L, Yan X, Fan Q, Liu H, Liu X, Liu Z, et al. D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19. J Thromb Haemost. 2020; 18 (6): 1324–9.
Hagger D, Wolff S, Owen J, Samson D. Changes in coagulation and fibrinolysis in patients with sickle cell disease compared with healthy black controls. Blood Coagul fibrinolysis an Int J Haemost Thromb. 1995 Apr; 6 (2): 93–9.
Fakunle E, Eteng K, Shokunbi W. D-D dimer levels in patients with sickle cell disease during bone pain crises and in the steady state. Pathol Lab Med Int. 2012; 4: 21–5.
Suwa T, Hogg JC, English D, Van Eeden SF. Interleukin-6 induces demargination of intravascular neutrophils and shortens their transit in marrow. Am J Physiol Heart Circ Physiol. 2000 Dec; 279 (6): H2954-60.